← Russell 3000 cross-section

RPRX Royalty Pharma plc

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$27.6bn
Revenue TTM
$2.5bn
Net income TTM
$815m
Free cash flow
Composite score
44.8
Sector rank
#355

Valuation

P / E
33.9
EV / EBITDA
23.3
EV / sales
14.0
FCF yield
Earnings yield vs 10-yr
-1.78pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
32.1%
EBITDA margin
59.8%
ROE
8.3%
ROIC
8.6%
Revenue growth
10.0%

Insider activity, last 90 days

Net open-market
$-23.16m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Our cash flow forecasts are updated each reporting period primarily using sell-side equity research analysts’ consensus sales estimates. Small declines in sell-side equity research analysts’ consensus sales forecasts over a long time horizon can result in an immediate non-cash income statement expense recognition, even though the applicable cash inflows will not be realized for many years into the future. For example, in late 2014 we acquired the cystic fibrosis franchise and shortly after, declines in near-term sales forecasts of sell-side equity research analysts caused us to recognize non-cash provision expense in our condensed consolidated statements of operations. …Royalty Pharma plc, 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →